| Jul 25 |
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
|
| Jul 22 |
Why Hims & Hers Heath Shares Are Surging Today
|
| Jul 19 |
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
|
| Jul 19 |
Teva reports positive data from Phase III paediatric migraine prevention trial
|
| Jul 18 |
Teva meets main goal in trial for its migraine prevention in children and adolescents
|
| Jul 18 |
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
|
| Jul 17 |
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
|
| Jul 17 |
3 No-Brainer Stocks to Buy With $200 Right Now
|
| Jul 12 |
U.S. Senate passes bill to trim Big Pharma "patent thickets"
|
| Jul 10 |
Argus upgrades Teva to buy, cites recent drug approvals
|
